Related Experiment Video
Updated: Apr 12, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
Published on: June 21, 2018
Evaluation of productivity in Iranian pharmaceutical companies: A DEA-based Malmquist approach and panel data
Mehdi Varmaghani1, Amir Hashemi Meshkini1, Farshad Farzadfar2
1Department of Pharmacoeconomics and Pharmaceutical Administration, Tehran University of Medical Sciences, Tehran, Iran ; Non-communicable Disease Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Objective:
In this study, we aimed to assess comparative productivity of 21 pharmaceutical companies in Iran during 2000-2013.
Methods:
To evaluate the productivity trend of pharmaceutical companies in Iran, we used data envelopment analysis-based Malmquist index. "Total assets" and "capital stock" as inputs and "net sales" and "net profit" as outputs extracted from Tehran stock exchange, were selected to be included in the analysis. This method provides the possibility for analyzing the performance of each company in term of productivity changes over time. We also used an estimation generalized least square panel data model to identify the factors that might affect productivity of pharmaceutical companies in Iran using EViews 7 and Deep 2.1 software.
Findings:
The mean total productivity during all years of the study was 0.9829, which indicates the improvement in their overall productivity. The results, over the 13-year period, indicated that the range of productivity changes in pharmaceutical companies, that were included in this study, was between 0.884 and 1.098. Panel data model indicated that age of company could positively (t = 4.765978, P < 0.001) and being located in cities other than Tehran (the capital) could negatively (t = -5.369549, P < 0.001) affect the productivity of pharmaceutical companies. The analysis showed the new policy (brand-generic scheme) and also the type of ownership did not have a significant effect on the productivity of pharmaceutical companies.
Conclusion:
In this study, pharmaceutical productivity trends were fluctuated that could be due to the sub-optimal attention of policy makers and managers of pharmaceutical companies toward long-term strategic planning, focusing on productivity improvement.
More Related Videos
05:47In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
Published on: August 28, 2019
07:58Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
Published on: February 24, 2023
Related Concept Videos
Therapeutic Drug Monitoring: Drug Analysis Methods
Analysis of Population Pharmacokinetic Data
Drug Dissolution: Requirements and Profile Comparison
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Measurement of Bioavailability: Pharmacodynamic Methods
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions